LEQEMBI Subcutaneous Autoinjector Shows Comparable Efficacy to IV in Alzheimer's Trial
BIIB sits 65% above its 52-week low of $121.05.
Summary
New clinical data presented at AAIC 2026 show that a once-weekly subcutaneous autoinjector formulation of LEQEMBI achieves drug exposure comparable to the approved IV regimen, with similar efficacy and safety in early Alzheimer's disease. The SC-AI achieved bioequivalence (104% exposure ratio) and consistent amyloid clearance across body weight groups, supporting a fixed-dose at-home option. Real-world data from two U.S. centers showed sustained cognitive benefit over 36 months. This follows Biogen's recent mixed Alzheimer's pipeline news, including the Phase 2 Celia study results and advancement of Diranersen. The SC formulation could significantly expand patient access and convenience, potentially strengthening LEQEMBI's commercial position. Regulatory submission timing was not disclosed.
At the time of this announcement, BIIB was trading at $199.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.4B. The 52-week trading range was $121.05 to $219.72. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.